Blog

Dec 15, 2016

Can naked mole rats teach us the secrets to living far longer? Google thinks so

Posted by in categories: biotech/medical, genetics, life extension

It is looking increasingly likely the mysterious Google Calico have very modest ambitions regarding increased lifespans for humans given the comments made by Dr. Aubrey de Grey and others and the direction they are taking with their research. Modest increases of lifespan over the kind of robust therapies of SENS seems pretty dissapointing.


More about Google Calico and their aim to modestly increase lifespan. People like Dr. Aubrey de Grey and Nathaniel David from rising biotech star Unity.

“To some, Calico’s heavy bet on basic biology is a wrong turn. The company is “my biggest disappointment right now,” says Aubrey de Grey, an influential proponent of attempts to intervene in the aging process and chief science officer of the SENS Research Foundation, a charity an hour’s drive from Calico that promotes rejuvenation technology. It is being driven, he complains, “by the assumption that we still do not understand aging well enough to have a chance to develop therapies.” Indeed, some competitors are far more aggressive in pursuing interventions than Calico is.

They are very committed to these fundamental mechanisms, and bless them for doing that. But we are committed to putting drugs into the clinic and we might do it first,” says Nathaniel David, president and cofounder of Unity Biotechnology. This year, investors put $127 million behind Unity, a startup in San Francisco that’s developing drugs to zap older, “senescent” cells that have stopped dividing. These cells are suspected of releasing cocktails of unhelpful old-age signals, and by killing them, Unity’s drugs could act to rejuvenate tissues. The company plans to start with a modestly ambitious test in arthritic knees. De Grey’s SENS Foundation, for its part, has funded Oisin Biotechnologies, a startup aiming to rid bodies of senescent cells using gene therapy.”

Read more

Comments are closed.